Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (451-460 of 692) with videos related to

Pageof 70
Sort By:
Endocrinology|March 14, 2009
A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatinEleanor F Need, Howard I Scher, Amelia A Peters, et al.
Science (New York, N.Y.)|January 13, 2022
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosisKjetil Bjornevik, Marianna Cortese, Brian C Healy, et al.
Plos One|September 9, 2010
Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancerMayu O Frank, Julia Kaufman, Suyan Tian, et al.
Frontiers in Bioscience : a Journal and Virtual Library|May 25, 2006
Novel mutations of epidermal growth factor receptor in localized prostate cancerDiah A Douglas, Hong Zhong, Jae Y Ro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancerMatthew D Galsky, Eric J Small, William K Oh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM TrialJimmy L Zhao, Karim Fizazi, Fred Saad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2012
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancerM J Morris, M A Eisenberger, R Pili, et al.
Investigational New Drugs|March 7, 2018
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancerLaura Graham, Kalyan Banda, Alba Torres, et al.
The Journal of Urology|September 11, 2019
<i>PTEN</i> Loss with <i>ERG</i> Negative Status is Associated with Lethal Disease after Radical ProstatectomyNora M Haney, Farzana A Faisal, Jiayun Lu, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2012
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumorsAbdulateef O Aregbe, Eric A Sherer, Merrill J Egorin, et al.
Pageof 70

Showing results (451-460 of 692) with videos related to

Sort By:
Pageof 70
Endocrinology|March 14, 2009
A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatinEleanor F Need, Howard I Scher, Amelia A Peters, et al.
Science (New York, N.Y.)|January 13, 2022
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosisKjetil Bjornevik, Marianna Cortese, Brian C Healy, et al.
Plos One|September 9, 2010
Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancerMayu O Frank, Julia Kaufman, Suyan Tian, et al.
Frontiers in Bioscience : a Journal and Virtual Library|May 25, 2006
Novel mutations of epidermal growth factor receptor in localized prostate cancerDiah A Douglas, Hong Zhong, Jae Y Ro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancerMatthew D Galsky, Eric J Small, William K Oh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM TrialJimmy L Zhao, Karim Fizazi, Fred Saad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2012
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancerM J Morris, M A Eisenberger, R Pili, et al.
Investigational New Drugs|March 7, 2018
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancerLaura Graham, Kalyan Banda, Alba Torres, et al.
The Journal of Urology|September 11, 2019
<i>PTEN</i> Loss with <i>ERG</i> Negative Status is Associated with Lethal Disease after Radical ProstatectomyNora M Haney, Farzana A Faisal, Jiayun Lu, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2012
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumorsAbdulateef O Aregbe, Eric A Sherer, Merrill J Egorin, et al.
Pageof 70